SuppreMol GmbH / SuppreMol announces presentation of clinical data for its lead product SM101 at the 54th ASH Annual Meeting . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
Phase Ib/IIa interim data in Primary Immune Thrombocytopenia (ITP) show an excellent safety profile and therapeutic activity
Munich, Germany, November 7, 2012: SuppreMol GmbH, a biopharmaceutical company focused on development of novel therapeutics for the treatment of autoimmune diseases, today announced that data of its lead product SM101 will be reported at the 54th American Hematology Society Annual Meeting, to be held December 8-11 in Atlanta, Georgia.
Abstract #: 3388
Title: Interim Results from a Phase Ib/IIa Clinical Trial with the Soluble Fc-gamma-IIB Receptor SM101 for the Treatment of Primary Immune Thrombocytopenia
Authors: Tatyana Semenovna Konstaninova, Ivanova Valentina Leonidovna, Andrzej Hellmann, Slawomira Kyrcz-Krzemien, Sascha Tillmanns, Peter Sondermann and Peter Buckel
Poster presentation: Monday, December 10, 6 - 8 PM ET
Location: Hall B1-B2, Level 1, Building B (Georgia World Congress Center), Session 331, Pathophysiology of Thrombosis, Poster III
Phase Ib data of an ongoing Phase Ib/IIa trial of SM101 in patients with ITP will be presented, including efficacy and safety data on 36 ITP patients and data on duration of response.
The Abstract can be found at https://ash.confex.com/ash/2012/webprogram/Paper47038.html (https://ash.confex.com/ash/2012/webprogram/Paper47038.html)
About SM101
SuppreMol's lead candidate SM101 is a recombinant, soluble, non-glycosylated version of the Fc-gamma-receptor IIB. The protein binds to autoantibody/autoantigen complexes and blocks the activation of Fc receptors on the surface of immune cells. As a result, the immune response is down regulated as is the associated inflammation cascade, typically observed in autoimmune diseases. The efficacy of SM101, including a reduction of inflammation and immune parameters, has been demonstrated in relevant animal models. At present, SM101 is being evaluated in a Phase II trial in Primary Immune Thrombocytopenia (ITP). SM101 has received orphan drug designation in the US and Europe for ITP. In addition, SM101 is being studied in a Phase II, double-blind clinical trial in patients with Systemic Lupus Erythematosus (SLE). SM101 also has a potential in a number of other B cell driven autoimmune diseases, including Rheumatoid Arthritis (RA).
About SuppreMol
SuppreMol GmbH is a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune and allergic diseases. The company is pioneering the development of soluble Fc-gamma receptors (FcgRs), which are recombinant autologous therapeutic proteins with a specific immunoregulatory potential. The company is developing FcgRs in two ongoing Phase II studies for the treatment of Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus (SLE) and potentially for Rheumatoid Arthritis (RA) and other autoimmune conditions. SuppreMol's pipeline includes two antibody development programs utilizing the inhibitory effect of FcgRIIB suitable for alternative treatment strategies and indications as well as an anti-IL-3 antibody to treat RA.
Contact
SuppreMol GmbH
Prof. Dr. Peter Buckel
Chief Executive Officer
Tel: +49 89 30 90 50 680
E-mail: info@suppremol.com (mailto:info@suppremol.com)
www.suppremol.com (http://www.suppremol.com/)
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: SuppreMol GmbH via Thomson Reuters ONE
--- End of Message ---
SuppreMol GmbH
Am Klopferspitz 19 Martinsried/Munich Germany
